MedTrace Logo

PTC in Personalizing Neoadjuvant Therapy for Patients With Advanced Gastrointestinal Tumor

NCT05280210 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2022-03-15

No results posted yet for this study

Summary

To explore the value of PTC drug screening technique in selecting neoadjuvant therapy for advanced gastrointestinal cancer.

Conditions

  • Gastrointestinal Neoplasms

Interventions

OTHER

PTC drug screening

PTC is an in vitro tumor model, which serves as a structural and functional unit recapitulating the original tumors in genotype, phenotype, and drug response. PTC will be used in drug screening.

Sponsors & Collaborators

  • Peking University

    lead OTHER

Principal Investigators

  • Aiwen Wu, M.D. · Peking University Cancer Hospital & Institute

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2023-12-31
Completion
2024-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05280210 on ClinicalTrials.gov